



NEWS ANNOUNCEMENT
CONTACT: Robin Baum at 440-392-7428

FOR IMMEDIATE RELEASE

**NEW RESERT™ XL HLD HIGH LEVEL DISINFECTANT IS A NON-SENSITIZING
ALTERNATIVE TO COMMONLY USED HIGH LEVEL DISINFECTION
CHEMISTRIES IN THE GI SUITE**

Resert oxidizing chemistry is safer for patients, staff and devices

MENTOR, OHIO – June 19, 2009 – Among the most pressing concerns of staff in the GI suite, one is heard most often – “we need an effective high-level disinfection solution for reprocessing our scopes that won’t pose a risk to our patients and staff.” Many outpatient centers have encountered sensitivity issues with today’s most commonly used high-level disinfectants. STERIS Corporation now offers Resert XL HLD High Level Disinfectant, a new non-aldehyde solution, for hospitals and health centers. Among its many benefits, *this formulation is non-sensitizing and has virtually no inhalation risk for staff and patients.*

“In my 25-plus years in surgical nursing, Resert XL HLD High Level Disinfectant is one of the very few products that have grabbed my attention,” comments Carol Imes, director of nursing at Mentor Surgical Center in Mentor, Ohio. “Our staff has used glutaraldehyde disinfectants for many years. I had wanted to switch to OPA, but I know it is associated with 'anaphylaxis-like' reactions after repeated cystoscopy in patients with a history of bladder cancer. Since urology is one of our key services, I am glad that the Resert formulation is an effective disinfectant that’s safer for all our patients. I’m now getting very positive feedback from my staff about the elimination of fumes, the milder odor, and the scopes looking “like new.” They also appreciate the much faster processing time – from a 20-minute soak to an 8-minute one – which is making turnover faster and resulting in happier surgeons. In addition, the 21-day useful life of Resert XL HLD disinfectant adds another week, or 50% more productivity, to our disinfection process.”

“This ready-to-use oxidative chemistry is a non-toxic, environmentally friendly, versatile alternative to aldehyde disinfectants,” states Chris Antonucci, product manager, STERIS Corporation. “The staff doesn’t need to measure or mix solution. Even better, Resert XL HLD disinfectant is versatile – it’s designed for both manual cleaning and automated endoscope

STERIS Corporation
News Announcement
Page 2

reprocessing, and can typically be re-used for up to 21 days. In addition, no special venting or disposal measures are needed; the solution is safely and easily rinsed down the drain. Resert XL HLD high-level disinfectant is also non-staining, virtually odorless, and leaves no toxic residues on devices. This marks a distinct new option for GI staff and their patients.”

Resert XL HLD High Level Disinfectant is a broad-based microbicide based on AHP™, a proprietary formulation from Virox Technologies that utilizes hydrogen peroxide as the active agent. It is designed for the high-level disinfection of heat-sensitive critical and semi-critical devices and surgical instruments. Its oxidative action does not promote biofilm formation and has been shown to leave no cytotoxic residues on medical instruments *after just one rinse*.

This non-toxic hydrogen peroxide concentration has several economic benefits for GI suites as well. It achieves high-level disinfection in only eight minutes at 68° F (20° C) and does not require additional heating in automated processors, which can improve processing productivity and save on energy costs. Furthermore, the Resert XL HLD chemistry can be reused for up to 21 days, making the per-scope cost comparable to other processes. There is no added cost for special ventilation or disposal, since the solution doesn't present an inhalation risk and is safely rinsed down the drain. And, because it is safe for most flexible endoscopes and their component materials, it can help to optimize their useful life.

A chemical indicator test strip is also available from STERIS to verify the correct minimum effective hydrogen peroxide concentration each time reprocessing is performed.

***AHP™ is a trademark of Virox Technologies, Inc., Oakville, Ontario, Canada. The AHP technology is the property of Virox Technologies, Inc., and is being used under license. The use of Resert™ XL HLD solution in an automated endoscope reprocessor must be part of a validated reprocessing protocol.*

About STERIS Corporation

The mission of STERIS Corporation is to provide a healthier today and safer tomorrow through knowledgeable people and innovative infection prevention, decontamination and health science technologies, products and services. The Company's more than 5,000 dedicated employees around the world work together to supply a combination of equipment, consumables and services to healthcare, pharmaceutical, industrial and government customers. The Company

STERIS Corporation
News Announcement
Page 3

is listed on the New York Stock Exchange under the symbol STE. For more information, please visit www.steris.com.

About Virox Technologies, Inc.

The mission of Virox Technologies is to equip the entire spectrum of global markets that are concerned with infection control with state-of-the-art antimicrobial technology in the war against germs. Our company is dedicated to the development, optimization, and adaptation of a fundamentally new approach to this challenge... an approach which has been validated and endorsed by the scientific community and which has been adopted by the market leaders in a broad range of industries. For more information, please visit www.virox.com.

####

Editor's Note: For additional product information and images, please contact Robin Baum: robin_baum@steris.com, or visit www.steris.com.

This news release may contain statements concerning certain expectations, forecasts, estimates, product performance or other forward-looking information affecting or relating to the Company or its products that are intended to qualify for the protections afforded "forward-looking statements" under the Private Securities Litigation Reform Act of 1995 and other laws and regulations. Forward-looking statements speak only as to the date of this report, and may be identified by the use of forward-looking terms such as "may," "will," "expects," "believes," "anticipates," "plans," "safer," "virtually," "typically" and "risk," or the negative of such terms or other variations on such terms or comparable terminology. Many important factors could cause actual results to differ materially from those in this news release including, without limitation, disruption of production or supplies, changes in product use, pending or future claims or litigation, competitive factors, technology advances, and changes in government regulations or the application or interpretation thereof. Other risk factors are described in the Company's Form 10-K and other securities filings. Many of these important factors are outside STERIS's control. No assurances can be provided as to any product performance or product safety unless all labeling, instructions for use, MSDS and other product literature are strictly followed. Unless legally required, the Company does not undertake to update or revise any forward-looking statements even if events make clear that any projected results, express or implied, will not be realized. Other potential risks and uncertainties that could cause actual results to differ materially from those in this news release include, without limitation, (a) the possibility that market demand will not develop for new technologies, products or application; (b) the possibility that application of or compliance with laws, court rulings, regulations, certifications or other requirements or standards may delay or prevent product introductions, affect the production and marketing of existing products, or otherwise affect product performance; or (c) uses not consistent with product instructions. Product descriptions and performances herein are for illustration only and do not modify labeling, warranties or other technical literature.